Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists

Author:

Kawakami Jun,Morales Alvaro

Abstract

Purpose:  We examined the serum levels of testosterone (T) (total and bioavailable) dehydroepiandrosterone (DHEA), follicle stimulating (FSH), luteinizing (LH), and prostate specific antigen (PSA) in men receiving treatment with  luteinizing hormone releasing-hormone (LHRH) agonists for metastatic prostate cancer, to determine the efficacy of these agents in lowering T levels and whether a possible  relationship exists between PSA values, as a surrogate measure of tumor activity, and hormone levels.   Materials and Methods:  This was a single center prospective study of patients on LHRH agonists.  Of all 100 eligible patients, 31 did not qualify: 10 were receiving their first injection, 13 were on intermittent hormonal therapy, 7 refused to enter the trial, and 1 patient’s blood sample was lost.  Therefore, 69 patients were included in the final analysis.  Each patient had their blood sample drawn immediately before the administration of a LHRH agonist. The new proposed criteria of <20ng/dL (0.69 nmol/L) of total testosterone was used to define optimal levels of the hormone in this population.   Results: Of the 69 patients, 41 were on goserelin injections, 21 on leuprolide, and 7 on buserelin.  There was no statistical difference in hormone levels between any of the medications.  Overall, 21% of patients failed to reach optimal levels of total testosterone. PSA levels were higher in this group.  There was a statistically significant correlation between PSA and testosterone levels as well as between PSA and  FSH.  Serum levels of PSA however, did not correlate with those of bio-available testosterone.   Conclusions: Failure to reach optimal levels of testosterone occurs in patients on LHRH agonist therapy.  Higher PSA values are more commonly found in patients with sub-optimal levels of testosterone receiving LHRH analogs but the clinical importance of this finding has not been established.  There is no significant difference with respect to hormonal levels reached among patients on a variety of LHRH agonists.  Total testosterone determinations should be considered in patients on LHRH agonist therapy, particularly when the PSA values begin to rise since it may lead to further beneficial hormonal manipulation.

Publisher

Canadian Urological Association Journal

Subject

Urology,Oncology

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3